The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day. Vertex (VRTX) has received quite a bit of attention from Zacks.com ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The radios in our list do a lot of other things besides bring you radio broadcasts. With built-in ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

(RTTNews) - L3Harris Technologies (LHX), Monday announced that the company has secured a contract worth nearly $300 million from the U.S. Army for full-rate production of Manpack and Leader radios ...

Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable ...